29
July 2024
IXICO plc
("IXICO" or the
"Company")
Further progress in HD
consortium
Presentation of biomarker results
and onboarding of new consortium partner
IXICO plc (AIM: IXI), the medical
imaging advanced analytics company delivering insights in
neuroscience reports further progress in
the Huntington's disease imaging harmonization (HD-IH) consortium
deploying IXICO's AI powered IXIQ.Ai analysis platform to develop
and validate imaging biomarkers for HD. HD-IH was previously
announced as a partnership between the CHDI Foundation, uniQure,
PTC Therapeutics, and Asklepios BioPharmaceutical, and IXICO is
pleased to announce the onboarding of an additional bio-pharma
partner to HD-IH in June 2024. Over the past year, the
expanding partnership has made significant progress in applying
IXIQ.Ai to more than 6,000 MRI scans available to the consortium
and generating the data required to demonstrate the utility of the
obtained biomarker measurements as clinical trial
endpoints.
IXICO's Dr Marina Papoutsi presented
preliminary findings at the annual HD-TC conference in February
2024 in a poster entitled "Association between regional volume change
and clinical change in Huntington's disease HD-ISS Stage 2 and
Stage 3 participant". The presentation provides further
evidence for the use of brain volume changes measured with IXIQ.Ai
as an alternative trial endpoint to traditional clinical outcomes
(surrogate endpoint). HD-IH continues to seek additional partners
to expand its biomarker development program.
Dr Robin Wolz, Chief Scientific
Officer of IXICO, commented:
"We are delighted with the progress
made in the HD-IH consortium over the past year. The results
presented at the HD-TC conference show how the initial data
generated via this partnership provides additional evidence of the
impact that MRI-based biomarkers have in HD clinical development.
This further expansion in the number of HD-IH biopharmaceutical
partners demonstrates the value this collaboration provides to the
industry.
By completing the analysis of the
available data over the remainder of 2024 and focusing on the
resulting biomarker evidence, the consortium will provide unique
scientific understanding and insights for successful operational
implementation of those measurements in clinical development."
For
further information please contact:
|
IXICO plc
|
+44 (0) 20
3763 7499
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated Adviser and Sole
Broker)
|
+44 (0) 20 7220
0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
|
| |
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More
information is available on www.IXICO.com and
follow us on Twitter @IXICOnews